Comparison of efficacy of intravenous peramivir and oral oseltamivir for the treatment of influenza: Systematic review and meta-analysis

Yonsei Medical Journal

Volumn 58, Issue 4, 2017, Pages 778-785

  Lee, Jonghoo ^a   Park, Ju Hee ^b   Jwa, Hyeyoung ^a   Kim, Yee Hyung ^c  

^a Jeju National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

Author keywords

Fever; Human; Influenza; Oseltamivir; Peramivir; Respiratory; Signs and symptoms

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE;

COMPARATIVE STUDY; DRUG EFFICACY; FEVER; HOSPITALIZATION; HUMAN; INFLUENZA; LENGTH OF STAY; MORTALITY RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; INFLUENZA, HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; ODDS RATIO; ORAL DRUG ADMINISTRATION; PUBLISHING; RISK FACTOR; VIROLOGY;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CYCLOPENTANES; GUANIDINES; HUMANS; INFLUENZA, HUMAN; ODDS RATIO; OSELTAMIVIR; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85019687403     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2017.58.4.778     Document Type: Review

References (19)

1. Vaccines against influenza WHO position paper-November 2012. Wkly Epidemiol Rec 2012;87:461-76.
2. Centers for Diseases Control and Prevention. Vaccine Recommendations of the ACIP [accessed on 2016 December 27]. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html.
3. Wester A, Shetty AK. Peramivir injection in the treatment of acute influenza: a review of the literature. Infect Drug Resist 2016;9:201-14.
4. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009;361: 2204-7.
5. Kohno S, Kida H, Mizuguchi M, Shimada J; S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010;54:4568-74.
6. Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011; 55:2803-12.
7. Ison MG, Hui DS, Clezy K, O’Neil BJ, Flynt A, Collis PJ, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 2013;18:651-61.
8. Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011;55:5267-76.
9. Hikita T, Hikita H, Hikita F, Hikita N, Hikita S. Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr 2012;2012:834181.
10. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, et al. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. J Infect Chemother 2012; 18:858-64.
11. Takemoto Y, Asai T, Ikezoe I, Yano T, Ichikawa M, Miyagawa S, et al. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. Chemotherapy 2013;59:373-8.
12. Yoo JW, Choi SH, Huh JW, Lim CM, Koh Y, Hong SB. Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza. J Med Virol 2015;87:1649-55.
13. Yoshino Y, Seo K, Koga I, Kitazawa T, Ota Y. Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. Clin Respir J 2015;9:228-32.
14. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if non-randomized studies in meta-analyses [accessed on 2016 December 27]. Available at: http://www.ohri.ca/programs/clinical_epidemi-ology/oxford.asp.
15. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
16. Alame MM, Massaad E, Zaraket H. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections. Front Microbiol 2016;7:450.
17. de Jong MD, Ison MG, Monto AS, Metev H, Clark C, O’Neil B, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 2014;59:e172-85.
18. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005;10:901-10.
19. Hata A, Akashi-Ueda R, Takamatsu K, Matsumura T. Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther 2014;8:2017-38.